The procedure using mitochondrial replacement therapy (MRT) resulted in the birth of a healthy baby boy to a carrier of Leigh Syndrome, a progressive, fatal neurological disorder caused by a mutation in the mother's mitochondrial DNA.
MRT enabled the parents to have a healthy child after the loss of two children to Leigh syndrome.
The parents of the baby, a Jordanian couple, had been trying to start a family for almost 20 years. After suffering four miscarriages and the death of their first two babies, couple sought out the help of John Zhang and his team at the New Hope Fertility Centre in New York City.
The mother is asymptomatic as her mutation load is only 24.5 per cent, less than half the expected 60 per cent threshold load for the disease.
Her son, born on April 6 last year after IVF with MRT, had a mutation load ranging from 2.36 to 9.23 per cent, depending on the tissues tested, well below the expected threshold for the condition. It is currently unknown whether the mutation load will remain the same throughout his life.
The researchers used an electrofusion technique to transfer the nuclear genome from the mother's egg (leaving behind most of the mother's mitochondria) to the cytoplasm of a donor egg containing only healthy mitochondria.
Two methods of cell fusion have been used in the past by various groups researching MRT.
Most groups have utilised a virus to accomplish cell fusion, however, the extent of viral DNA carryover is unknown.
The other method involves a metered electrical pulse to initiate cell fusion. Comparably, electrofusion is a more demanding technically, but has no risk of viral DNA carryover.
The ovarian stimulation and egg collection procedures, mitochondrial replacement and fertilisation were carried out at a private fertility clinic in New York.
"Thirty years ago it was discovered that certain rare diseases are associated with abnormal, mutated mitochondria in human cells," said Jacques Cohen, Director of the ART Institute of Washington.
"It is only now that the combination of this knowledge-base and clinical strategy has allowed the birth of a baby free of mitochondrial disease, after decades of ethical and political debate," said Cohen.
The research was published in the journal Reproductive BioMedicine Online (RBMO).
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
